About ESSA Pharma
ESSA Pharma is a company based in Vancouver (Canada) founded in 2009 was acquired by Alexis Bio in July 2025. It operates as a HealthTech. ESSA Pharma has raised $16.38 million across 10 funding rounds from investors including Pfizer, Blackstone and Alexis Bio. ESSA Pharma has completed 1 acquisition, including Realm Therapeutics. ESSA Pharma offers products and services including Masofaniten (EPI-7386). ESSA Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Vancouver, Canada
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Essa Pharma Inc.
-
Annual Revenue
Not available
-
Net Profit
-$28.54 M (USD)-7as on Sep 30, 2024
-
EBITDA
Not available
-
Total Equity Funding
$16.38 M (USD)
in 10 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Jan 12, 2021
-
Investors
Pfizer
& 6 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Alexis Bio
(Jul 14, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ESSA Pharma
ESSA Pharma is a publicly listed company on the NASDAQ with ticker symbol EPIX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ESSA Pharma
ESSA Pharma offers a comprehensive portfolio of products and services, including Masofaniten (EPI-7386).
Novel therapy targeting androgen receptor for prostate cancer.
People of ESSA Pharma
Unlock access to complete
Unlock access to complete
Leadership Team
9 people
Scientific Team
1 people
Finance and Accounting
1 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of ESSA Pharma
ESSA Pharma has successfully raised a total of $16.38M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ESSA Pharma
ESSA Pharma has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Blackstone and Alexis Bio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked |
Investor details for ESSA Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ESSA Pharma
ESSA Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Realm Therapeutics.
Investment portfolio details for ESSA Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Immunomodulatory formulations for the treatment of eye and skin inflammation.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for ESSA Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - ESSA Pharma
Detailed financials for ESSA Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Essa Pharma Comparisons
Peer comparison for ESSA Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ESSA Pharma
ESSA Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of ESSA Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Essa Pharma
Complete news archive for ESSA Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ESSA Pharma
ESSA Pharma was founded in 2009 and raised its 1st funding round 5 years after it was founded.
ESSA Pharma is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
David Parkinson is the current CEO of ESSA Pharma.
ESSA Pharma is a funded company, having raised a total of $16.38M across 10 funding rounds to date.
ESSA Pharma is engaged in the development of novel therapies for prostate cancer treatment. The company operates in the healthcare sector, specifically targeting oncology through innovative approaches. Its lead candidate, masofaniten (EPI-7386), is designed to disrupt the androgen receptor signaling pathway, a key driver of prostate cancer growth. Solutions are developed to complement existing treatments by targeting the N-terminal domain of the androgen receptor, addressing resistance mechanisms in current therapies. Clinical trials, including monotherapy and combination studies, are conducted to evaluate efficacy and safety in patients with castration-resistant prostate cancer.
ESSA Pharma's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
ESSA Pharma offers Masofaniten (EPI-7386).
Yes, ESSA Pharma is publicly traded on NASDAQ under the ticker symbol EPIX.
ESSA Pharma has made 1 acquisition, including Realm Therapeutics.
ESSA Pharma has 7 investors. Key investors include Pfizer, Blackstone, Alexis Bio, Omega Funds, and CPRIT.
The ticker symbol of ESSA Pharma is EPIX on NASDAQ.